These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38746089)

  • 21. The Brain Penetrating and Dual TORC1/TORC2 Inhibitor, RES529, Elicits Anti-Glioma Activity and Enhances the Therapeutic Effects of Anti-Angiogenetic Compounds in Preclinical Murine Models.
    Gravina GL; Mancini A; Colapietro A; Delle Monache S; Sferra R; Pompili S; Vitale F; Martellucci S; Marampon F; Mattei V; Biordi L; Sherris D; Festuccia C
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31640252
    [No Abstract]   [Full Text] [Related]  

  • 22. Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins.
    Ziegler DS; Wright RD; Kesari S; Lemieux ME; Tran MA; Jain M; Zawel L; Kung AL
    J Clin Invest; 2008 Sep; 118(9):3109-22. PubMed ID: 18677408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Culture dimensionality influences the resistance of glioblastoma stem-like cells to multikinase inhibitors.
    Fernandez-Fuente G; Mollinedo P; Grande L; Vazquez-Barquero A; Fernandez-Luna JL
    Mol Cancer Ther; 2014 Jun; 13(6):1664-72. PubMed ID: 24723451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myosin 10 Regulates Invasion, Mitosis, and Metabolic Signaling in Glioblastoma.
    Kenchappa RS; Mistriotis P; Wisniewski E; Bhattacharya S; Kulkarni T; West R; Luu A; Conlon M; Heimsath E; Crish JF; Picariello HS; Dovas A; Zarco N; Lara-Velazquez M; Quiñones-Hinojosa A; Hammer JA; Mukhopadhyay D; Cheney RE; Konstantopoulos K; Canoll P; Rosenfeld SS
    iScience; 2020 Dec; 23(12):101802. PubMed ID: 33299973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma.
    Pitter KL; Galbán CJ; Galbán S; Tehrani OS; Li F; Charles N; Bradbury MS; Becher OJ; Chenevert TL; Rehemtulla A; Ross BD; Holland EC; Hambardzumyan D
    PLoS One; 2011 Jan; 6(1):e14545. PubMed ID: 21267448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The kinase inhibitor SI113 induces autophagy and synergizes with quinacrine in hindering the growth of human glioblastoma multiforme cells.
    Matteoni S; Abbruzzese C; Matarrese P; De Luca G; Mileo AM; Miccadei S; Schenone S; Musumeci F; Haas TL; Sette G; Carapella CM; Amato R; Perrotti N; Signore M; Paggi MG
    J Exp Clin Cancer Res; 2019 May; 38(1):202. PubMed ID: 31101126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
    Jiang P; Mukthavaram R; Chao Y; Bharati IS; Fogal V; Pastorino S; Cong X; Nomura N; Gallagher M; Abbasi T; Vali S; Pingle SC; Makale M; Kesari S
    J Transl Med; 2014 Jan; 12():13. PubMed ID: 24433351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small molecule tyrosine kinase inhibitors in glioblastoma.
    Kim G; Ko YT
    Arch Pharm Res; 2020 Apr; 43(4):385-394. PubMed ID: 32239429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
    Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
    Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR blockade in GBM brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate compensatory mechanisms in vitro and in vivo.
    Jensen KV; Hao X; Aman A; Luchman HA; Weiss S
    Neurooncol Adv; 2020; 2(1):vdaa020. PubMed ID: 32226941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma.
    Narayan RS; Gasol A; Slangen PLG; Cornelissen FMG; Lagerweij T; Veldman HYYE; Dik R; van den Berg J; Slotman BJ; Würdinger T; Haas-Kogan DA; Stalpers LJA; Baumert BG; Westerman BA; Theys J; Sminia P
    Mol Cancer Ther; 2018 Feb; 17(2):347-354. PubMed ID: 28958992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacologic modulation of nasal epithelium augments neural stem cell targeting of glioblastoma.
    Spencer D; Yu D; Morshed RA; Li G; Pituch KC; Gao DX; Bertolino N; Procissi D; Lesniak MS; Balyasnikova IV
    Theranostics; 2019; 9(7):2071-2083. PubMed ID: 31037157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endogenous species of mammalian nonmuscle myosin IIA and IIB include activated monomers and heteropolymers.
    Shutova MS; Spessott WA; Giraudo CG; Svitkina T
    Curr Biol; 2014 Sep; 24(17):1958-68. PubMed ID: 25131674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
    Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
    Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Gonçalves CS; Vieira de Castro J; Pojo M; Martins EP; Queirós S; Chautard E; Taipa R; Pires MM; Pinto AA; Pardal F; Custódia C; Faria CC; Clara C; Reis RM; Sousa N; Costa BM
    Theranostics; 2018; 8(17):4805-4823. PubMed ID: 30279739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival.
    Herzog S; Fink MA; Weitmann K; Friedel C; Hadlich S; Langner S; Kindermann K; Holm T; Böhm A; Eskilsson E; Miletic H; Hildner M; Fritsch M; Vogelgesang S; Havemann C; Ritter CA; Meyer zu Schwabedissen HE; Rauch B; Hoffmann W; Kroemer HK; Schroeder H; Bien-Möller S
    Neuro Oncol; 2015 Feb; 17(2):223-42. PubMed ID: 25155357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
    Ning S; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment.
    Sidorov M; Dighe P; Woo RWL; Rodriguez-Brotons A; Chen M; Ice RJ; Vaquero E; Jian D; Desprez PY; Nosrati M; Galvez L; Leng L; Dickinson L; Kashani-Sabet M; McAllister SD; Soroceanu L
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
    de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS
    Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.